Sharon Genato
Internal Medicine · Torrance, CANPI 1902906555
Payments from drug & device makers
Across 146 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Pfizer$796
- Biohaven Pharmaceuticals, Inc.$393
- AbbVie$268
- Esperion Therapeutics, Inc.$151
- plus $1K from 19 others
What the payments were for
- Consulting fees$58310%
- Food & beverage$5,06288%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $1,978 |
| Novo Nordisk | 44 | $1,108 |
| Pfizer | 25 | $796 |
| Biohaven Pharmaceuticals, Inc. | 4 | $393 |
| AbbVie | 8 | $268 |
| Esperion Therapeutics, Inc. | 3 | $151 |
| Amgen | 6 | $145 |
| Eisai Inc. | 3 | $136 |
| Astellas Pharma US Inc | 3 | $116 |
| Merck | 2 | $95 |
| Redhill Biopharma Inc. | 2 | $70 |
| Bausch Health US, LLC | 3 | $61 |
| Novartis | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| EMD Serono, Inc. | 1 | $50 |
| Johnson & Johnson | 2 | $44 |
| Lilly USA, LLC | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $38 |
| Genentech USA, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,755 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $9,604 |
| Atorvastatin Calcium | 75 | $589 |
| Lisinopril | 23 | $210 |
| Losartan Potassium | 18 | $168 |
| Levothyroxine Sodium | 19 | $120 |
| Carvedilol | 13 | $117 |
| Metformin Hcl ErMetformin Hcl | 11 | $106 |
| Furosemide | 11 | $94 |
| Amlodipine Besylate | 35 | $94 |
| Metformin Hcl | 17 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $38 | $9,60428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Torrance
- Robert JendersTorrance$5.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.